Clinical-stage gene editing company Intellia Therapeutics Inc (NASDAQ:NTLA) and ReCode Therapeutics, a clinical-stage genetic medicines company, announced on Thursday a strategic collaboration aimed at developing novel genomic medicines to treat cystic fibrosis (CF).

Leveraging Intellia's CRISPR-based platform and ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery system, the collaboration targets precise correction of CF disease-causing gene mutations.

Initial efforts will focus on patients with limited or no treatment options, with potential expansion later on. Intellia will lead the design of editing strategies and provide research-grade components for the investigational therapies, while ReCode will handle preclinical and clinical development, as well as global commercialisation for certain programmes arising from the collaboration.

Intellia stands to receive development and commercial milestone payments, along with royalties, and retains the option to lead commercialisation in the US for certain programmes.